Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Glucovance in Type 2 Diabetes
NCT00035568Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2002
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of glibenclamide + metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Second-phase insulin response during a hyperglycaemic clamp at 20 weeks. Started Feb 2002; status: completed.
02
Drugs
glibenclamide + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00035568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035568.